NewsRoom Articles - Page 22 of 154 - PsychedelicNewsWire (PNW)

TuesdayOct 03, 2023 2:13 pm

More Psychiatrists View Use of Psychedelics in Treating Mental Disorders Positively

A recently published study has found that more than 80% of psychiatrists positively view the use of psychedelic substances in treating a range of mental-health conditions. For the study, researchers from different institutions including Case Western Reserve University, Harvard Medical School and Yale University School of Medicine, sent surveys to an estimated one thousand resident fellows and attending psychiatrists. Participants were required to assess statements on psychedelics, ranking them on a scale of strongly agree to strongly disagree. These statements included the use of psychedelics in treating substance-use disorders, the legalization of psychedelics for medical use and whether therapists would…

MondayOct 02, 2023 12:17 pm

Survey Suggests Psychedelics Are Effective Against Chronic Pain

A recent survey of over 150 volunteers has revealed that micro- and macrodoses of classic psychedelics may be able to alleviate chronic pain. Published in the “European Journal of Pain,” the study adds to the growing body of literature connecting psychedelics such as psilocybin (magic mushrooms), mescaline, DMT and LSD with reductions in chronic pain. Although the psychedelic research field is still in its infancy, most studies focus on the potential benefits and risks of using psychedelics to treat a myriad of mental-health issues. However, researchers have also discovered that psychedelics may also have applications in chronic pain treatment. In…

FridaySep 29, 2023 3:37 pm

Study Finds Psilocybin Users Less Inclined to Work Overtime

“Quiet quitting” is a phenomenon where employees put in the minimum effort, time and enthusiasm required of them at their jobs and don’t go out of their way to create any extra value for their employers. The trend has picked up a lot of steam in recent years as employees have begun prioritizing a strict work-life balance and finding value in their hobbies and other experiences rather than work. Increased employee demands and stagnating wages coupled with increasing living costs have made many employees question if going the extra mile, whether it's through arriving early, taking part in nonmandatory meetings…

ThursdaySep 28, 2023 2:45 pm

Report Forecasts $7.2B Market for Psychedelics by 2029

Psychedelics are projected to enjoy a compound annual growth rate (CAGR) of 55% and achieve a $7.2 billion valuation by 2029. A recent report from data and analytics firm GlobalData revealed that the psychedelic drug market is poised to experience robust growth before the end of the decade thanks to positive developments on the legislative and regulatory side. The past couple of years have seen an exponential rise in public and scientific psychedelic interest thanks to a plethora of studies associating hallucinogens such as psilocybin, LSD and ayahuasca with significant improvements in mental health. A growing body of research has…

WednesdaySep 27, 2023 1:04 pm

Enthea Announces Nationwide Availability of Ketamine Treatment to Employees

Massachusetts-based healthcare provider Enthea has revealed that it is now offering psychedelic-assisted therapy coverage in employee healthcare plans nationwide. The provider was in the news last year when soap company Dr. Bronners announced that it would be offering psychedelic-assisted therapy coverage to its employees via Enthea. Around 7% of Dr. Bronners’ employees signed up for the psychedelics benefit package, and the company says those employees experienced “dramatic improvements” in their mental health. Nonprofit healthcare Enthea will now extend the coverage to patients across the entire United States as ancillary benefits in employee healthcare plans. Enthea focuses on ketamine-assisted therapy and…

TuesdaySep 26, 2023 2:52 pm

Michigan Lawmaker Revives Efforts to Legalize Psychedelic Fungi, Plants

A Michigan lawmaker has relaunched efforts to legalize psychedelic fungi and plants with the caveat that all psychedelic-related activity does not involve monetary exchange. Sponsored by Senator Jeff Irwin, Senate Bill 449 would legalize mescaline, psilocybin, dimethyltryptamine (DMT), psilocin and ibogaine as well as the plants and fungi that produce these five psychedelics. The measure would allow the noncommercial cultivation, manufacturing, delivery and possession of the five psychedelics and remove penalties for simple possession. Michigan currently classifies the simple possession of the five covered hallucinogens as a misdemeanor. Irwin introduced a similar measure in late 2021 that would have legalized…

MondaySep 25, 2023 2:09 pm

Why Element of Play Needs More Attention in Conversations About Psychedelics

After decades of criminalization in most countries across the world, psychedelics are finally having their moment in the light. Early research in the 1950s and 1960s indicated that psychedelics had some therapeutic potential, but new drug-safety policies from the FDA halted further research efforts and relegated psychedelic use to a select few. However, recent successes in drug-reform campaigns in the United States has given psychedelics another chance without the mostly political barriers that prevented its research in decades past. A growing body of scientific literature now shows that psychedelics such as LSD, psilocybin, ayahuasca and DMT may have the ability…

FridaySep 22, 2023 12:59 pm

Study Shows Neuroplasticity Boosted After One Dose of Psilocybin

New research has revealed that a single dose of psilocybin, the main psychoactive agent in psychedelic mushrooms, can boost neuroplasticity in users. Scientists found that the psychedelic was capable of inducing neural changes that were associated with reductions in depression symptoms. Neuroplasticity refers to the brain and nervous system’s ability to change and adapt to interior or exterior stimuli by reorganizing neural connections, functions and structure. Researchers have been looking for ways to harness neuroplasticity and use it to treat mental disorders such as major depressive disorder (MDD) and addiction disorders. Psychedelics represent a new frontier in psychiatry that could…

ThursdaySep 21, 2023 12:06 pm

High Demand Characterizes Launch of Legal Psilocybin Access in Oregon

This June, America’s first-ever service center for psilocybin-assisted therapy opened in Oregon, marking both the state and country’s first definitive steps toward legalizing therapeutic psilocybin for the masses. Oregon is the first state in the country to offer psilocybin-related treatments; the state went a step further in June by opening the first center where eligible adults could experience guided psilocybin trips. Epic Healing Eugene will give Oregonians aged 21 years and older the opportunity to experience guided psychedelic trips for around six hours without the need for referrals or prescriptions. The center currently has more than 3,000 people on its…

WednesdaySep 20, 2023 1:13 pm

Reports Say MDMA Could Get FDA Consideration for Approval Next Year

New research has found that patients suffering from moderate to severe PTSD may experience a reduction in their symptoms following treatment with MDMA. The study, which was sponsored by the Multidisciplinary Association for Psychedelic Studies (MAPS), published its findings in the “Nature” journal. Rick Doblin, president and founder of Multidisciplinary Association for Psychedelic Studies (MAPS), believes that MDMA-assisted therapy is on course for approval by the Food and Drug Administration (FDA) in 2024, thanks to the efforts of many therapists, participants and donors. The study, which involved a randomized, placebo-controlled, double-blinded trial, recruited 104 individuals with PTSD who received either…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000